Skip to main content
. 2020 Dec 9;55:45–54. doi: 10.1016/j.breast.2020.12.004

Fig. 2.

Fig. 2

Local relapse-free survival (LRFS) for molecular subtypes of invasive tumors and for in situ carcinoma (ISC) group of patients. Although all the data have been used for statistical analyses, here, for graphic purposes only, the plot was curtailed at 9 years, since the proportion of patients experiencing the event after 120 months was negligible.